X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (314) 314
female (162) 162
male (157) 157
vinca alkaloids - adverse effects (151) 151
middle aged (116) 116
index medicus (111) 111
vinca alkaloids - therapeutic use (109) 109
animals (105) 105
aged (104) 104
adult (95) 95
oncology (90) 90
vinca alkaloids (90) 90
antineoplastic agents - adverse effects (88) 88
cancer (70) 70
chemotherapy (70) 70
pharmacology & pharmacy (66) 66
neoplasms - drug therapy (65) 65
vinca alkaloids - pharmacology (57) 57
vinca alkaloids - administration & dosage (54) 54
vinblastine - analogs & derivatives (50) 50
antineoplastic agents - therapeutic use (46) 46
treatment outcome (40) 40
vinca alkaloid (37) 37
vinblastine - adverse effects (35) 35
antineoplastic agents, phytogenic - adverse effects (34) 34
vincristine (34) 34
vinorelbine (33) 33
medicine & public health (31) 31
vinblastine - therapeutic use (31) 31
antineoplastic agents (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
mice (29) 29
aged, 80 and over (28) 28
antineoplastic agents - administration & dosage (28) 28
clinical trials as topic (28) 28
vinblastine - administration & dosage (28) 28
care and treatment (27) 27
rats (27) 27
vinblastine (27) 27
breast neoplasms - drug therapy (26) 26
dose-response relationship, drug (26) 26
antineoplastic agents, phytogenic - therapeutic use (24) 24
adolescent (22) 22
antineoplastic agents, phytogenic - administration & dosage (22) 22
alkaloids (21) 21
drug administration schedule (21) 21
drug therapy (21) 21
lung neoplasms - drug therapy (21) 21
paclitaxel (21) 21
vinflunine (21) 21
clinical neurology (20) 20
drugs (20) 20
hematology (20) 20
peripheral nervous system diseases - chemically induced (20) 20
antimitotic agents (19) 19
antineoplastic agents - pharmacology (19) 19
pharmacokinetics (19) 19
research (19) 19
taxoids - adverse effects (19) 19
vincristine - adverse effects (19) 19
breast cancer (18) 18
cerebrovascular disorders - drug therapy (18) 18
drug interactions (18) 18
neurosciences (18) 18
risk factors (18) 18
vinpocetine (18) 18
administration, oral (17) 17
neurotoxicity (17) 17
antineoplastic agents, phytogenic - pharmacology (16) 16
breast-cancer (16) 16
cell lung-cancer (16) 16
drug evaluation (16) 16
injections, intravenous (16) 16
taxanes (16) 16
cisplatin (15) 15
hematology, oncology and palliative medicine (15) 15
hodgkin disease - drug therapy (15) 15
in-vitro (15) 15
infusions, intravenous (15) 15
microtubules - drug effects (15) 15
neuropathy (15) 15
phase-ii (15) 15
time factors (15) 15
acute lymphoblastic-leukemia (14) 14
antineoplastic agents - pharmacokinetics (14) 14
antineoplastic agents, phytogenic - pharmacokinetics (14) 14
antitumor-activity (14) 14
children (14) 14
health aspects (14) 14
pharmacology/toxicology (14) 14
retrospective studies (14) 14
therapy (14) 14
tubulin (14) 14
vinblastine - pharmacokinetics (14) 14
vinblastine - pharmacology (14) 14
antibiotics, antineoplastic - adverse effects (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
child (13) 13
drug resistance, neoplasm (13) 13
folic acid - analogs & derivatives (13) 13
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (333) 333
Russian (14) 14
French (12) 12
German (11) 11
Japanese (6) 6
Hungarian (5) 5
Italian (4) 4
Spanish (3) 3
Dutch (2) 2
Chinese (1) 1
Danish (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4400 - 4406
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 4/2018, Volume 26, Issue 4, pp. 1019 - 1028
Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy... 
Pain Medicine | Nursing | Rehabilitation Medicine | Exercise | Medicine & Public Health | Nursing Research | Oncology | CIPN | Neuropathy | MANAGEMENT | PREVENTION | PREVALENCE | CANCER SURVIVORS | PAIN | ONCOLOGY | PREDICTORS | CLINICAL-TRIALS | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | PHYSICAL-ACTIVITY | QUALITY-OF-LIFE | OUTCOMES | Exercise Therapy - methods | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Vinca Alkaloids - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Peripheral Nervous System Diseases - therapy | Male | Peripheral Nervous System Diseases - physiopathology | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Taxoids - administration & dosage | Organoplatinum Compounds - administration & dosage | Vinca Alkaloids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Female | Neoplasm Staging | Neoplasms - pathology | Bridged-Ring Compounds - administration & dosage | Organoplatinum Compounds - adverse effects | Taxoids - adverse effects | Alkaloids | Chemotherapy | Health aspects | Analysis | Mortality | Cancer | Clinical trials | Breast cancer | Peripheral neuropathy | Index Medicus | exercise | neuropathy
Journal Article
Blood Reviews, ISSN 0268-960X, 2014, Volume 29, Issue 2, pp. 93 - 100
Abstract The number of available therapies for hematologic malignancies continues to grow at a rapid pace. Unfortunately, many of these treatments carry both... 
Hematology, Oncology and Palliative Medicine | Delirium | Chemotherapy | Seizure | Neuropathy | Toxicity | Encephalopathy | ADVERSE DRUG EVENTS | NERVOUS-SYSTEM TOXICITY | BRENTUXIMAB VEDOTIN | HIGH-DOSE CYTARABINE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | CHRONIC LYMPHOCYTIC-LEUKEMIA | PERIPHERAL NEUROPATHY | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | PHASE-I | Hematologic Neoplasms - therapy | Immunoconjugates - toxicity | Neurotoxicity Syndromes - diagnosis | Humans | Rituximab - toxicity | Antineoplastic Agents - toxicity | Brain Diseases - chemically induced | Seizures - chemically induced | Vinca Alkaloids - toxicity | Antineoplastic Agents - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Brain Diseases - etiology | Hematologic Neoplasms - complications | Angiogenesis Inhibitors - adverse effects | Immunoconjugates - adverse effects | Rituximab - adverse effects | Brain Diseases - diagnosis | Vinca Alkaloids - adverse effects | Seizures - diagnosis | Immunotherapy - adverse effects | Neurotoxicity Syndromes - etiology | Organoplatinum Compounds - toxicity | Animals | Antibodies, Bispecific - adverse effects | Angiogenesis Inhibitors - toxicity | Seizures - etiology | Hematologic Neoplasms - drug therapy | Antibodies, Bispecific - toxicity | Organoplatinum Compounds - adverse effects | Cancer | toxicity | neuropathy | seizure | encephalopathy | delirium
Journal Article
Journal Article
European Journal of Clinical Investigation, ISSN 0014-2972, 03/2016, Volume 46, Issue 3, pp. 264 - 284
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2009, Volume 49, Issue 12, pp. 1467 - 1476
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2/2015, Volume 23, Issue 2, pp. 513 - 524
Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancer patients who undergo chemotherapy with platinum analogues, taxanes, vinca alkaloids,... 
Pain Medicine | Anticonvulsants | Chemotherapy | Nursing | Rehabilitation Medicine | Medicine & Public Health | Antidepressants | Oncology | Peripheral neuropathy | Nursing Management/Nursing Research | Cancer